Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Ohio: - Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
- Bethesda North Hospital — Cincinnati, Ohio
- TriHealth Cancer Institute-Westside — Cincinnati, Ohio
- TriHealth Cancer Institute-Anderson — Cincinnati, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Sites in Ohio: - Gabrail Cancer Center — Canton, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Cleveland Clinic Cancer Center Fairview Hospital Moll Pavilion — Cleveland, Ohio
- Taussig Cancer Insititute Cleveland Clinic — Cleveland, Ohio
- Cleveland Clinic Cancer Center Independence Family Health Center — Independence, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Sponsor: Incyte Corporation
NCT ID: NCT07284849
Sites in Ohio: - University of Cincinnati Cancer Institute — Cincinnati, Ohio
- Case Comprehensive Cancer Center — Cleveland, Ohio
- Ohio State University-Arthur G James Comprehensive Cancer Center — Columbus, Ohio
- Ohio Health — Columbus, Ohio
- Zangmeister Center — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Ohio: - Gabrail Cancer Center — Canton, Ohio
- University Hospital of Cleveland — Cleveland, Ohio
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Ohio: - Case Western Reserve University — Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Saint Elizabeth Youngstown Hospital — Youngstown, Ohio
Phase 3 Recruiting Industry
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…
Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in Ohio: - GSK Investigational Site — Akron, Ohio
- GSK Investigational Site — Cincinnati, Ohio
- GSK Investigational Site — Cleveland, Ohio
- GSK Investigational Site — Cleveland, Ohio
- GSK Investigational Site — Cleveland, Ohio
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Ohio: - The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Ohio: - Miami Valley Hospital South ( Site 0075) — Centerville, Ohio
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Sites in Ohio: - Oncology Hematology Care - Blue Ash /ID# 280143 — Cincinnati, Ohio
Phase 3 Recruiting Academic/Other
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Sponsor: Johns Hopkins University
NCT ID: NCT02000089
Sites in Ohio: - Case Comprehensive Cancer Center, Case Western Medical Reserve — Cleveland, Ohio
Phase 2 Recruiting Academic/Other
This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Ohio: - Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- MetroHealth Medical Center — Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Miami Valley Hospital — Dayton, Ohio
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Ohio: - Local Institution - 2112 — Canton, Ohio
- Local Institution - 2143 — Cincinnati, Ohio
- Local Institution - 2109 — Cleveland, Ohio
- The Ohio State University Wexner Medical Center — Columbus, Ohio
- Local Institution - 2119 — Toledo, Ohio
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Ohio: - Oncology Hematology Care Primary — Cincinnati, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Ohio: - The Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
- Ohio State University — Columbus, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Ohio: - Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 2 Recruiting Industry
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line …
Sponsor: Oncolytics Biotech
NCT ID: NCT07446322
Sites in Ohio: - Gabrail Cancer Center — Canton, Ohio
Phase 2 Recruiting Industry
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combin…
Sponsor: AbbVie
NCT ID: NCT06820463
Sites in Ohio: - Oncology Hematology Care - Eastgate /ID# 271493 — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Ohio: - Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with adva…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Ohio: - The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 2 Recruiting Industry
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Sponsor: NGM Biopharmaceuticals, Inc
NCT ID: NCT07033026
Sites in Ohio: - NGM Clinical Study Site — Toledo, Ohio
- NGM Clinical Study Site — Youngstown, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uv…
Sponsor: IDEAYA Biosciences
NCT ID: NCT03947385
Sites in Ohio: - University of Cincinnati Cancer Center — Cincinnati, Ohio
- The Cleveland Clinic Foundation — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesoth…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06051695
Sites in Ohio: - The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Ohio: - Ohio State University — Columbus, Ohio